GLAXOSMITHKLINE PHARMACEUTICALS
|
|
| BOM : 500660 NSE : GLAXO | |
| LT :
Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
| ST :
Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
May 23,2025 |
|
Price(EOD): ₹ 3,021.55
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 51,185.06 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| GLAXOSMITHKLINE PHARMACEUTICALS | 7.1% | 6% | 28.1% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.7% | -5.9% | 12.4% |
| DIVIS LABORATORIES | -1.6% | 9.5% | 66.5% |
| CIPLA | -0.5% | -3.2% | 4.5% |
| TORRENT PHARMACEUTICALS | -3.9% | -4.8% | 18.8% |
| DR REDDYS LABORATORIES | 0.9% | 3.7% | 5.1% |
| MANKIND PHARMA | -4.9% | -4.4% | 15.5% |
| ZYDUS LIFESCIENCES | -0.4% | 4.6% | -18.2% |
| LUPIN | -2.5% | -5.3% | 18.6% |
FUNDAMENTAL ANALYSIS OF GLAXOSMITHKLINE PHARMACEUTICALS
[ Q(TTM): Mar2025, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF GLAXOSMITHKLINE PHARMACEUTICALS
[As on : May 23,2025
]
| Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
55.18
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 927.58 Cr
[Latest Qtr - Mar2025 - Consolidated Results ] 26.23
P/B Calculated based on Book Value of Rs 1,951.31 Cr
[Latest Year - Mar2025 - Consolidated Results ] 13.65
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 3,749.21 Cr
[Latest Qtr - Mar2025 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
62% 58% 56% |
SHARE PRICE MOMENTUM OF GLAXOSMITHKLINE PHARMACEUTICALS
GLAXOSMITHKLINE PHARMACEUTICALS vs SENSEX
DEBT OF GLAXOSMITHKLINE PHARMACEUTICALS
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2024 2023 2022 Avg_3yrs |
0 0 0 - |
0 0 0 - |
|
[Last Annual Data : Mar2024]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF GLAXOSMITHKLINE PHARMACEUTICALS
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2025 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF GLAXOSMITHKLINE PHARMACEUTICALS
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
2.63% 14.14% 16.38% 14.35% |
4.79% 29.51% 32.5% 35.17% |
| QtrlyTrend |
8 | |
| Latest Qtr: Mar2025 | ||
| Quarterly Result Analysis → | ||
GLAXOSMITHKLINE PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE HEALTHCARE | 0.2% | 0.5% | 19.9% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY 500 EQUAL WEIGHT | 0.4% | 4.6% | NA |
| NIFTY MIDSMALL HEALTHCARE | 0.3% | -0% | 21.2% |
| NIFTY MIDSMALLCAP 400 | NA | 4.2% | 7.1% |
| NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | -0.1% | 3.7% | NA |
| NIFTY500 MULTICAP 50:25:25 | -0.2% | 3.5% | 7.8% |
You may also like the below Video Courses
FAQ about GLAXOSMITHKLINE PHARMACEUTICALS
Is GLAXOSMITHKLINE PHARMACEUTICALS good for long term investment?
As on May 23,2025, the Fundamentals of GLAXOSMITHKLINE PHARMACEUTICALS look Strong and hence it may be good for long term investment! See Financial Performance of GLAXOSMITHKLINE PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is GLAXOSMITHKLINE PHARMACEUTICALS UnderValued or OverValued?
As on May 23,2025, GLAXOSMITHKLINE PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of GLAXOSMITHKLINE PHARMACEUTICALS ?
As on May 23,2025, the Intrinsic Value of GLAXOSMITHKLINE PHARMACEUTICALS is Rs. 1,908.01 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 1,860.45
Fair Value [Median EV / Sales Model] : Rs. 1,908.01
Fair Value [Median Price / Sales Model] : Rs. 1,936.02
Estimated Median Fair Value of GLAXOSMITHKLINE PHARMACEUTICALS : Rs. 1,908.01
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
